Docetaxel and prostate cancer;Docetaxel et cancer de la prostate

Bulletin du Cancer

Volumn 91, Issue 2, 2004, Pages 172-177

  Ferrero, Jean Marc ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Chemotherapy; Docetaxel; Prostate cancer

Indexed keywords

ANTIANDROGEN; DOCETAXEL; ESTRAMUSTINE; HYDROCORTISONE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID; TAXANE DERIVATIVE; VINBLASTINE;

ASTHENIA; BIOCHEMISTRY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FATIGUE; HUMAN; LACRIMATION; METASTASIS; MICROTUBULE ASSEMBLY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SIDE EFFECT; SURVIVAL; SYMPTOMATOLOGY; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 1842610059     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Bubley G, Carducci M, Dahut W, Dawson M, Daliani D, Eisenberger M, et al. Eligibility and response guide lines for phase II clinical trials in androgen-independant prostate cancer : recommendations. From the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 ; 17 : 3461-7.
2. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993 ; 11 : 607-15.
3. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993 ; 71 : 1098-109.
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer : a Canadian randomized trial with palliative end points. J Clin Oncol 1996 ; 14 : 1756-64.
5. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer : results of the Cancer and Leukemia Group B 9 182 study. J Clin Oncol 1999 ; 17 : 2506-13.
6. Craft N, Shostak Y, Carey M, Sawyers J. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER62/neu tyrosine kinase. Nature Med 1999 ; 5 : 280-5.
7. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein Bd-2 in hormone-refractory human prostate cancers. Am J Pathol 1993 ; 143 : 390-400.
8. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone refractory prostate cancer : a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999 ; 17 : 3160-6.
9. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997 ; 15 : 3156-63.
10. Athanasiadis A, Tsavdaridis D, Athanassiades I, Pergantas N, Roussos G, Rigatos SK, et al. Paclitaxel (P) and estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC) : a phase II study. Proc Am Soc Clin Oncol 2001 ; 20 : 755 (abstr.).
11. Kelly W, Curley T, Slavin S, Heller G, Mc Caffrey J, Bajorin D, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001 ; 19 : 44-53.
12. Picus J, Schultz M, Cochrane J. A phase II trial of docetaxel in patients with hormone-refractory prostate cancer (HRPC) : long term results. Proc Am Soc Clin Oncol 1999 ; 18 : 1206 (abstr.)
13. Friedland D, Cohen J, Miller R, Voloshin M, Gluckman R, Lembersky B, et al. A phase II trial of docetaxel (Taxotere) in hotmone-refractory prostate cancer : correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999 ; 26 (suppl.) : 19-23.
14. Briasoulis E, Karavasilis V, Anastasopoulos D, Tzamakov E, Fountzilas G, Rammou D, et al. Weekly docetaxel in minimally pretreated patients : a dose-escalation study focused on feasability and toxicity of long-term administration. Ann Oncol 1999 ; 10 : 701-6.
15. Berry W, Rohrbaugh T. The American Oncology Resosurces Clinical Research Task Force : phase II trial of single-agent, weekly (Wk) Taxotere (T) in symptomatic, hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1999 ; 18 : 1290 (abstr.).
16. Gravis G, Bladou F, Salem N, Macquart-Moulin G, genre D, Carmelo J, et al. Efficacy, quality of life (QOL) and tolerance with weekly docetaxel (D) in metastatic hormone-refractory prostate cancer (HRPC) patients. Proc Am Soc Clin Oncol 2001; 20: 2433 (abstr.).
17. Foa C, Ferrero JM, Thezenas S, Ronchin P, Peyrade F, Valenza B, et al. A phase II of weekly docetaxel for hormone refractory metastatic prostate cancer. Ann Oncol 2002; 13 (suppl.): 95.
18. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17: 958-67.
19. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone-refractory prostate carcinoma. Ann Oncol 1999; 10: 33-8.
20. Natale RB, Zaretsky SL. Phase I/II trial of estramustine (E) and Taxocere (T) in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1999; 348a: 1343 (abstr.).
21. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-16.
22. Petrylak DP, Shelton GB, England-Owen C, Pfaff C, Bagliella E, Diuleo R, et al. Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (Pts) with androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 2000; 19: 1312 (abstr.).
23. Sinibaldi VJ, Carducci MA, Moorev-Cooper S, Laufer M, Eisenberger MA. A phase II study evaluting docetaxel (D) and one day of estramustine phosphate (EMP) in patients (Pts) with hormone-refractory prostate cancer (HRPC) Updated preliminary analysis. Proc Am Soc Clin Oncol 2000; 19: 1361 (abstr.).
24. Kosty MP, Ferreira A, Bryntesen T. Weekly docetaxel and low-dose estramustine phosphate in hormone-refractory prostate cancer : a phase II study. Proc Am Soc Clin Oncol 2001; 20: 2360 (abstr.).
25. Petrilak DP. Chemotherapy for the treatment of hormone-refractory prostate cancer. European Urology 2002 (suppl. 1): 15-23.
26. Oudard S, Banu E, Vannetzel JM, Beuzeboc P. Results of a phase II randomized trial of docetaxel (D), estramustine (E) and prednisone (P) - two schedules - versus mitoxantrone (M) and prednisone in patients with hormone refractory prostate cancer. Ann Oncol 2002; 13 (suppl. 5): 325 (abstr.).
27. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Hormonal treatment before radical prostatectomy : a 3-year follow-up. J Urol 1998; 159: 2013-6.
28. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
29. Kumar P, Perotti M, Weiss R, Todd M, Cummings K, Di Paola R. A nouvel therapeutic strategy testing the safety and feasability of concomitant docetaxel and 3-D conformal radiation therapy in patients with high risk localized adenocarcinoma of the prostate : progress report of ongoing phase 1 trial. Proc Am Soc Clin Oncol 2002; 21: 772 (abstr.).
30. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al. Phase II evaluation of oral estramustine and oral etoposide in hormonen-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-12.
31. Pienta KJ, Olson KB. Treatment of metastatic hormone-refractory prostate cancer with estramustine (Emcyt) and vinorelbine. Proc Am Soc Clin Oncol 2001; 20: 2421 (abstr.).
32. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I : preclinical experience. Anti-cancer Drugs 1995; 6: 339-68.